Panagiota Pappou

Ms. Panagiota Pappou

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
ABAnastasia Bothou
Anastasia Bothou
ABAngeliki Bolou
Angeliki Bolou
KDKonstantinos Dinas
Konstantinos Dinas
GKGiannoula Alexios Kyrkou
Giannoula Alexios Kyrkou
DHDeniece Hardy
Deniece Hardy
ADAthina Diamanti
Athina Diamanti
Background: Breast cancer (BC) remains one of the leading causes of cancer-related deaths worldwide, with early detection being essential for improving survival rates, treatment outcomes, and preventive women’s healthcare strategies. Artificial Intelligence (AI), particularly deep learning (DL) and machine learning (ML) algorithms, has emerged as a promising tool for improving the accuracy and efficiency of BC diagnosis. This systematic review explores the role of AI in early BC detection and its implications for preventive and patient-centered women’s healthcare. Methods: A comprehensive search was conducted in PubMed and Scopus for studies published between January 2015 and December 2025, following PRISMA guidelines. The search strategy included combinations of MeSH terms and free-text keywords related to artificial intelligence, machine learning, deep learning, BC screening, mammography, magnetic resonance imaging (MRI), ultrasound, and BC detection. Eleven studies involving approximately 148,170 participants were included. Methodological quality was assessed according to study design. Results: AI-driven diagnostic systems demonstrated improved accuracy, sensitivity, specificity, and efficiency compared with conventional approaches. AI applications in mammography and ultrasound reduced radiologists’ workload and healthcare costs while enhancing cancer detection rates, particularly in women with high breast density. AI models also showed potential in identifying metastases and predicting clinical outcomes, supporting more efficient patient management and follow-up care. Conclusions: AI-based tools represent a promising advancement in BC detection and screening efficiency. Their integration into BC screening programs may strengthen preventive women’s healthcare services and improve patient outcomes. However, further large-scale clinical validation and real-world implementation studies are required before widespread clinical implementation.

14 October 2026 in Cancer Plus
Verified
Journal Article
Open access
PDF file
ATAlexios Tsochrinis
Alexios Tsochrinis
PPPanagiota Pappou
Panagiota Pappou
KGKleanthi Gourounti
Kleanthi Gourounti
EPERMIONI PALASKA
ERMIONI PALASKA
ADANNA DELTSIDOU
ANNA DELTSIDOU
ABAnastasia Bothou
Anastasia Bothou
Breast cancer during pregnancy presents unique therapeutic challenges, as effective maternal treatment must be balanced against potential risks to fetal and neonatal health. This systematic review aims to evaluate current evidence regarding the safety and effectiveness of chemotherapy during pregnancy in women with breast cancer (BC). This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search was conducted in PubMed, Google Scholar, Scopus, and the Open Inter-university Consortium for Political and Social Research databases. Following the search and selection process, a total of 14 articles met the inclusion criteria. Risk of bias was assessed using design-specific Joanna Briggs Institute critical appraisal tools. The administration of specific chemotherapy regimens, mainly anthracyclines, after the first trimester was generally not associated with an apparent increase in congenital abnormalities or perinatal mortality. However, an increased risk of preterm birth was observed, with a substantial proportion of preterm deliveries being iatrogenic. Furthermore, available comparative evidence did not indicate substantially worse maternal oncological outcomes attributable to pregnancy itself. Taken together, these findings suggest that chemotherapy for BC during pregnancy can be administered with relative safety after the first trimester, within an individualized treatment approach and close collaboration among obstetricians, oncologists, and neonatologists. Nevertheless, further multicenter studies are required to fully elucidate long-term neonatal outcomes.